Non-invasive biomarker in prostate carcinoma: A novel approach

Indian Journal of Clinical Biochemistry

Volumn 28, Issue 2, 2013, Pages 107-109

  Dwivedi, Shailendra ^a   Shukla, Kamla Kant ^a   Gupta, Geetanjali ^a   Sharma, Praveen ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CARCINOMA IN SITU; EDITORIAL; EPIGENETICS; GENOMICS; HUMAN; PROSTATE CARCINOMA; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

EID: 84886364616     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-013-0312-5     Document Type: Editorial

References (14)

1. Philip H, Amman B, Deborah E, Ben C, Aphrodite I, Mary W. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14.
2. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate. 2008;68:1097-104.
3. Yegnasubramanian S, Wu Z, Haffner MC, Esopi D, Aryee MJ, Badrinath R, et al. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics. 2011;12:313.
4. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 2004;10:8472-8.
5. Willard SS, Koochekpour S. Regulators of gene expression as biomarkers for prostate cancer. Am. J. Cancer Res. 2012;2(6):620-57.
6. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer. 2011;10:38.
7. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Miller LS, Miick S, et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011;3:94ra72.
8. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130-5.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008;105:10513-8.
10. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230-4.
11. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis. 2008;11:216-29.
12. Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S, Pant KK. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac. J. Cancer Prev. 2011;12:1843-8.
13. Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, et al. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate. 2011;71:268-80.
14. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 2003;21:3573-9.